Viewing Study NCT06881992


Ignite Creation Date: 2025-12-24 @ 3:21 PM
Ignite Modification Date: 2026-02-03 @ 8:21 PM
Study NCT ID: NCT06881992
Status: RECRUITING
Last Update Posted: 2025-10-21
First Post: 2025-03-10
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism
Sponsor: Rezolute
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Tumor Hyperinsulinism (Tumor HI) View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Doege-Potter Syndrome View
None Ectopic insulinoma View
None Extra-pancreatic insulinoma View
None Fibrosarcoma View
None HCC View
None Hyperinsulinemia View
None Hypoglycemia View
None Hypoglycemia due to fibrosarcoma View
None Hypoglycemia due to HCC View
None Hypoglycemia due to liposarcoma View
None Hypoglycemia due to tumor/cancer View
None IGF 2 Insulinoma View
None IGF 2 mediated non islet cell tumor hypoglycemia View
None IGF-2 mediated hypoglycemia View
None IGF-2, Big IGF-2 View
None IGF-oma, IGF-2-oma, Big IGF-2-oma View
None Insulinoma View
None Islet cell tumor (ICT) View
None Liposarcoma View
None Neuroendocrine tumor (NET) View
None NICTH View
None Non Islet Cell Tumor View
None Non-islet cell tumor hypoglycemia (NICTH) View
None Paraneoplastic View
None Paraneoplastic hypoglycemia View
None PNET View
None Pro-insulinoma View
None Tumor/cancer associated hypoglycemia View
None Tumor/cancer induced hypoglycemia View
None Tumor/cancer mediated hypoglycemia View
None Clinical Trials for: -Insulinoma -proinsulinoma -extrapancreatic insulinoma -non-islet cell tumor … View